Approval of Lenvatinib as a therapy medication for Advanced Kidney Cancer

Lenvima is classified under the category of targeted therapy. The main aim for the medication which comes under this category is to target something specific to the cancer cells.

Lenvatinib commonly known as Lenvima (manufactured by Eisai), was approved by US Food and Drug Administration in 2016 for the treatment of advanced kidney cancer. This medication has been approved solely for the patients whose cancer has progressed even after receiving treatment from medications which blocks the tumour growth.

Source: https://shorturl.at/dekrZ

#AdvancedKidneyCancer
#KidneyCancerTreatment
#LenvatinibApproved
#NewHopeForRCC
#CancerResearchMatters
#ClinicalTrialsWork
#Lenvatinib #RCC
#TargetedTherapy
#MultikinaseInhibitor
#ProgressionFreeSurvival
#KidneyCancerCommunity
#RCCStrong
#NeverGiveUp
#YouAreNotAlone
#cancerfighter